Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its fourth quarter and year-end 2024 financial results announcement for Wednesday, February 26, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and recent corporate progress.
Investors can access the call via U.S./Toll-Free number +1 833 470 1428 or International number +1 404 975 4839 using passcode 126145. A webcast option is also available through the Events & Presentations section on Mirum's website, with a replay accessible for 30 days.
Mirum Pharmaceuticals (NASDAQ: MIRM) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'anno 2024 per mercoledì 26 febbraio 2025. L'azienda ospiterà una conferenza telefonica alle 16:30 ET / 13:30 PT nello stesso giorno per discutere i risultati finanziari e i recenti progressi aziendali.
Gli investitori possono accedere alla chiamata tramite il numero U.S./Toll-Free +1 833 470 1428 o il numero internazionale +1 404 975 4839 utilizzando il codice di accesso 126145. È disponibile anche un'opzione di webcast nella sezione Eventi e Presentazioni sul sito web di Mirum, con una registrazione accessibile per 30 giorni.
Mirum Pharmaceuticals (NASDAQ: MIRM) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año 2024 para miércoles, 26 de febrero de 2025. La compañía llevará a cabo una llamada de conferencia a las 4:30 p.m. ET / 1:30 p.m. PT el mismo día para discutir los resultados financieros y los recientes avances corporativos.
Los inversores pueden acceder a la llamada a través del número gratuito de EE. UU. +1 833 470 1428 o el número internacional +1 404 975 4839 usando el código de acceso 126145. También hay una opción de webcast disponible a través de la sección de Eventos y Presentaciones en el sitio web de Mirum, con una repetición accesible durante 30 días.
미룸 제약(Mirum Pharmaceuticals) (NASDAQ: MIRM)은 2024년 4분기 및 연말 재무 결과 발표를 2025년 2월 26일 수요일로 예정했습니다. 회사는 같은 날 오후 4시 30분 ET / 오후 1시 30분 PT에 재무 결과 및 최근 기업 진행 사항에 대해 논의하기 위한 컨퍼런스 콜을 개최할 것입니다.
투자자는 미국/무료 전화번호 +1 833 470 1428 또는 국제 전화번호 +1 404 975 4839를 통해 126145 비밀번호를 사용하여 콜에 접속할 수 있습니다. 미룸 웹사이트의 이벤트 및 발표 섹션을 통해 웹캐스트 옵션도 제공되며, 30일 동안 재생할 수 있습니다.
Mirum Pharmaceuticals (NASDAQ: MIRM) a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 pour mercredi 26 février 2025. La société organisera une conférence téléphonique le même jour à 16h30 ET / 13h30 PT pour discuter des résultats financiers et des récents progrès de l'entreprise.
Les investisseurs peuvent accéder à l'appel via le numéro gratuit américain +1 833 470 1428 ou le numéro international +1 404 975 4839 en utilisant le code d'accès 126145. Une option de webdiffusion est également disponible dans la section Événements et Présentations sur le site web de Mirum, avec une rediffusion accessible pendant 30 jours.
Mirum Pharmaceuticals (NASDAQ: MIRM) hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Jahr 2024 auf Mittwoch, den 26. Februar 2025 terminiert. Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse und die jüngsten Unternehmensfortschritte zu erörtern.
Investoren können an dem Anruf über die US-/gebührenfreie Nummer +1 833 470 1428 oder die internationale Nummer +1 404 975 4839 mit dem Zugangscode 126145 teilnehmen. Eine Webcast-Option ist ebenfalls über den Bereich Veranstaltungen und Präsentationen auf der Website von Mirum verfügbar, mit einem Replay, das 30 Tage lang zugänglich ist.
- None.
- None.
Conference call details:
Wednesday, February 26, 2025
4:30 p.m. ET / 1:30 p.m. PT
Dial-in:
International: + 1 404 975 4839
Passcode: 126145
You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum's late-stage pipeline includes investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219189370/en/
Investor Contacts:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
FAQ
When will Mirum Pharmaceuticals (MIRM) release Q4 and full-year 2024 earnings?
What time is MIRM's Q4 2024 earnings conference call?
How can investors access MIRM's Q4 2024 earnings call?
How long will MIRM's Q4 2024 earnings call replay be available?
